The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
UNAIDS has raised the alarm on new HIV infections among adults and the need to step up prevention efforts with 1.9 million adults becoming infected with HIV globally each year since 2010.
Only one in six of the 29 million people who are dependent on drugs are accessing the vital treatment and support services they need, according to new data released by United Nations Office on Drugs and Crime (UNODC).
25 million transgender people experience difficulties in accessing services that can help them feel supported and keep them both physically and mentally healthy, according to a landmark Lancet series on transgender health.
The US President’s Emergency Plan for AIDS Relief (PEPFAR) has created an investment fund of US $100 million for populations most affected by HIV, including men who have sex with men (MSM), sex workers, people who use drugs, prisoners and transgender people.
At least two million more people were accessing HIV treatment globally in 2015 than a year earlier, according to new data from UNAIDS.
More than 20 organisations representing the voices of people who use drugs and LGBT communities have been banned by their countries from attending next month’s UN General Assembly High-Level Meeting on Ending AIDS.
HIV criminalisation is a growing global issue that is threatening effective HIV prevention, treatment and support, according to a new report from the HIV Justice Network and the Global Network of People Living with HIV (GNP+).
Doctors at Georgetown University in the USA have reported the first diagnosed case of Alzheimer’s disease in a person living with HIV. It was previously thought that HIV-related inflammation in the brain may prevent amyloid deposition – one of the likely causes of Alzheimer’s disease.
UNAIDS update indicates that US$ 26.2 billion is required to build sufficient momentum by 2020, to end AIDS by 2030, compared to an earlier estimate of US$ 30 billion.
A once-a-week injection that can offer ‘complete viral-load suppression’ for up to 17 months, could be available from 2017 according to Pharmaceutical company CytoDyn Inc. following a trial of 23 patients.